Type 1 Diabetes Clinical Trial
Official title:
Treatment of Mild-to-moderate Hypoglycemia in Adults With Type 1 Diabetes: a Validation Study
NCT number | NCT03489967 |
Other study ID # | HYPO-T |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 18, 2018 |
Est. completion date | August 31, 2020 |
Verified date | September 2020 |
Source | Institut de Recherches Cliniques de Montreal |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
According to guidelines, when a mild-to-moderate hypoglycemia occurs (capillary blood glucose < 4.0 mmol/L), 15-20g of rapidly absorbed carbohydrates should be ingested. Patients should re-test and re-ingest 15-20g carbohydrates every 15 minutes until they recover from hypoglycemia. These recommendations were principally based on two studies conducted in the 80s before the introduction of intensive insulin therapy secondary to the DCCT trial and with insulin formulations with largely different pharmacokinetic profiles from current insulin analogs. Recent studies suggest that with current insulin analogs and intensive therapeutic approach, 15g of carbohydrates may be insufficient to rapidly correct an important proportion of hypoglycemic episodes. It is thus important to determine if the recommended hypoglycemia treatment remains the recommendation.
Status | Completed |
Enrollment | 29 |
Est. completion date | August 31, 2020 |
Est. primary completion date | August 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Males and females = 18 years of old. 2. Clinical diagnosis of type 1 diabetes for at least one year. 3. Treatment with multiple daily insulin injections or insulin pump therapy and using insulin analogs (rapid, ultra-rapid and basal). 4. HbA1c = 10%. Exclusion Criteria: 1. Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator. 2. Recent (< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. 3. Known significant cardiac rhythm abnormality based on investigator judgment. 4. Abnormal blood panel and/or anemia (Hb < 100g/L). 5. Ongoing pregnancy or breastfeeding. 6. Severe hypoglycemic episode within 1 month of screening. 7. Known uncorrected hypokalemia (potassium < 3.5 mmol/L; available within the past 3 months). |
Country | Name | City | State |
---|---|---|---|
Canada | Institut de recherches cliniques de Montréal | Montréal |
Lead Sponsor | Collaborator |
---|---|
Institut de Recherches Cliniques de Montreal |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in glucose levels 15 minutes after hypoglycemic treatment | Change in glucose levels 15 minutes after hypoglycemic treatment (16g vs. 32g of carbohydrates) when glucose levels at the time of treatment are below 3.0 mmol/L or between 3.0 and 3.5 mmol/L. | 15 minutes after hypoglycemic treatment | |
Secondary | Change in glucose levels 20 minutes after hypoglycemic treatment | Change in glucose levels 20 minutes after hypoglycemic treatment (16g vs. 32g of carbohydrates) when glucose levels at the time of treatment are below 3.0 mmol/L or between 3.0 and 3.5 mmol/L. | 20 minutes after hypoglycemic treatment | |
Secondary | Change in glucose levels 30 minutes after hypoglycemic treatment | Change in glucose levels 30 minutes after hypoglycemic treatment (16g vs. 32g of carbohydrates) when glucose levels at the time of treatment are below 3.0 mmol/L or between 3.0 and 3.5 mmol/L. | 30 minutes after hypoglycemic treatment | |
Secondary | Change in glucose levels 45 minutes after hypoglycemic treatment | Change in glucose levels 45 minutes after hypoglycemic treatment (16g vs. 32g of carbohydrates) when glucose levels at the time of treatment are below 3.0 mmol/L or between 3.0 and 3.5 mmol/L. | 45 minutes after hypoglycemic treatment | |
Secondary | Change in glucose levels 60 minutes after hypoglycemic treatment | Change in glucose levels 60 minutes after hypoglycemic treatment (16g vs. 32g of carbohydrates) when glucose levels at the time of treatment are below 3.0 mmol/L or between 3.0 and 3.5 mmol/L. | 60 minutes after hypoglycemic treatment | |
Secondary | Number of participants with glucose levels above 8.0 mmol/L 1 hour after hypoglycemia correction | 60 minutes after hypoglycemia correction | ||
Secondary | Number of participants with glucose levels above 10.0 mmol/L 1 hour after hypoglycemia correction | 60 minutes after hypoglycemia correction | ||
Secondary | Glucose levels 60 minutes after meal consumption | 60 minutes after meal consumption | ||
Secondary | Glucose levels 90 minutes after meal consumption | 90 minutes after meal consumption | ||
Secondary | Number of patients for whom hypoglycemia was corrected 10 minutes after hypoglycemic treatment | 10 minutes after hypoglycemic treatment | ||
Secondary | Number of patients for whom hypoglycemia was corrected 15 minutes after hypoglycemic treatment | 15 minutes after hypoglycemic treatment | ||
Secondary | Number of patients for whom hypoglycemia was corrected 20 minutes after hypoglycemic treatment | 20 minutes after hypoglycemic treatment | ||
Secondary | Number of patients for whom hypoglycemia was corrected 25 minutes after hypoglycemic treatment | 25 minutes after hypoglycemic treatment | ||
Secondary | Number of patients for whom hypoglycemia was corrected 30 minutes after hypoglycemic treatment | 30 minutes after hypoglycemic treatment | ||
Secondary | Number of patients for whom hypoglycemia was corrected 35 minutes after hypoglycemic treatment | 35 minutes after hypoglycemic treatment | ||
Secondary | Number of hypoglycemic events corrected 10 minutes after hypoglycemic treatment | 10 minutes after hypoglycemic treatment | ||
Secondary | Number of hypoglycemic events corrected 15 minutes after hypoglycemic treatment | 15 minutes after hypoglycemic treatment | ||
Secondary | Number of hypoglycemic events corrected 20 minutes after hypoglycemic treatment | 20 minutes after hypoglycemic treatment | ||
Secondary | Number of hypoglycemic events corrected 25 minutes after hypoglycemic treatment | 25 minutes after hypoglycemic treatment | ||
Secondary | Number of hypoglycemic events corrected 30 minutes after hypoglycemic treatment | 30 minutes after hypoglycemic treatment | ||
Secondary | Number of hypoglycemic events corrected 35 minutes after hypoglycemic treatment | 35 minutes after hypoglycemic treatment | ||
Secondary | Number of patients for whom hypoglycemia symptoms disappeared 10 minutes after hypoglycemic treatment | 10 minutes after hypoglycemic treatment | ||
Secondary | Number of patients for whom hypoglycemia symptoms disappeared 15 minutes after hypoglycemic treatment | 15 minutes after hypoglycemic treatment | ||
Secondary | Number of patients for whom hypoglycemia symptoms disappeared 20 minutes after hypoglycemic treatment | 20 minutes after hypoglycemic treatment | ||
Secondary | Number of patients for whom hypoglycemia symptoms disappeared 25 minutes after hypoglycemic treatment | 25 minutes after hypoglycemic treatment | ||
Secondary | Number of patients for whom hypoglycemia symptoms disappeared 30 minutes after hypoglycemic treatment | 30 minutes after hypoglycemic treatment | ||
Secondary | Number of patients for whom hypoglycemia symptoms disappeared 35 minutes after hypoglycemic treatment | 35 minutes after hypoglycemic treatment | ||
Secondary | Number of patients requiring a second treatment 40 minutes after the first hypoglycemic treatment | 40 minutes after the first hypoglycemic treatment | ||
Secondary | Number of patients requiring a second treatment 15 minutes after the first hypoglycemic treatment | 15 minutes after the first hypoglycemic treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 |